Pliant Therapeutics (PLRX)

• Market cap: $86.3M
• 1 day: 2.92%
• 5 days: -4.08%
• 1 month: 2.17%
• 3 months: -89.38%
• 6 months: -87.08%
• Year to date: -89.38%
• 1 year: -90.40%
• 5 years: -93.38%
• 10 years: -93.38%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Employees: 171

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

28% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 43

20% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]

17% more capital invested

Capital invested by funds: $728M [Q3] → $853M (+$125M) [Q4]

6% more funds holding

Funds holding: 151 [Q3] → 160 (+9) [Q4]

1.66% more ownership

Funds ownership: 104.76% [Q3] → 106.42% (+1.66%) [Q4]

88% less call options, than puts

Call options by funds: $1.27M | Put options by funds: $10.7M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 6% upside
• Avg. target: $3.92 178% upside
• High target: $10 609% upside

6 analyst ratings

• positive: 0 0%
• neutral: 6 100%
• negative: 0 0%

Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target	6% upside $1.50	Neutral Maintained	4 Mar 2025
RBC Capital Brian Abrahams 14% 1-year accuracy 10 / 70 met price target	113% upside $3	Sector Perform Maintained	4 Mar 2025
Wells Fargo Tiago Fauth 33% 1-year accuracy 9 / 27 met price target	113% upside $3	Equal-Weight Maintained	4 Mar 2025
Needham Joseph Stringer 18% 1-year accuracy 22 / 122 met price target	609% upside $10	Hold Downgraded	4 Mar 2025
Leerink Partners Faisal Khurshid 17% 1-year accuracy 2 / 12 met price target	42% upside $2	Market Perform Downgraded	3 Mar 2025